Remove Biobanking Remove Genotype Remove Research
article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

Generation of strong research dataset cohorts must begin with high-quality clinical samples. Biobanks are used for the coordination of high-yield patient sample collection. The webinar highlighted the importance of maximizing utility and sustainability for the long-term success of biorepositories and biobanks.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

One of the reasons is because researchers now have far more genetic data to work with than was ever previously possible. With such a drop in cost, this means that researchers can test far more often and work with far more genetic data than previously possible. In this way, the company is able to generate drug targets.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Radiological Society of North America, Nov. 29-Dec. 5

The Pharma Data

The conference featured scientific papers in a number of subspecialties covering the newest trends in radiological research as well as education and informatics exhibits. The researchers found that food and housing insecurity were both associated with a longer lapse between diagnostic breast imaging and biopsy. 29 to Dec. 29 to Dec.

article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

Pharmaceutical companies and biotechs are also adapting their approaches, launching patient finding and engagement programmes that can start years before clinical trials begin and allow them to run ‘recontact by genotype’ studies that the Resilience Project would have liked to do. Why should research be any different?

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

In their 2013 paper published in the journal Hypertension , an international team of researchers describe how they performed a GWAS study using data from over 22,000 individuals with coronary artery disease and over 64,000 controls. This increased study power comes at the cost of applicability and validity of results.